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ABSTRACT
MUTANT PREVENTION CONCENTRATION OF MEROPENEM FOR
MEROPENEM SENSITIVE AND RESISTANT
ACINETOBACTER BAUMANNII FROM ISOLATES OF ICU PATIENTS
Dewi Retnoningsih
Acinetobacter baumannii are opportunistic bacteria that are being
increasingly implicated in severe nosocomial infections. Meropenem is commonly
used for the treatment of infections with these organisms for critically ill patients.
However, there are increasing reports of meropenem resistance among these
bacteria worldwide. Meropenem resistance in Acinetobacter baumannii may occur
through several mechanisms, which include outer membrane changes, production
of efflux pumps, and -lactamases production to hydrolyze meropenem. Several
approaches have been done to decrease the emergence of resistance during the
treatment course in order to improve treatment outcomes and keep the antibiotics
for future use. One such approach is the implementation of the Mutant Prevention
Concentration (MPC). The MPC is a pharmacodynamic parameter that is aimed at
suppressing the emergence of resistance throughout antimicrobial treatment. It is
defined as the concentration that prevent the growth of the first stepmutants. The
Mutant Selection Window (MSW) or MPC/MIC ratio is the difference between
the MPC and the MIC (Minimum Inhibitory Concentration) and it describes the
concentration range in which microorganisms tend to mutate and are selected for.
Purpose: The aim of this study are to determine MPC of meropenem for
Acinetobacter baumannii isolates from ICU patients, to analyze the MPC
difference of meropenem among clinical isolates of meropenem sensitive and
resistant Acinetobacter baumannii, and to determine MPC/MIC ratio of
meropenem among clinical isolates of meropenem sensitive and resistant
Acinetobacter baumannii.
Method: A total of 6 clinical isolates of meropenem sensitive and 20
clinical isolates of meropenem resistant Acinetobacter baumannii were tested. The
MIC was determined according to the CLSI guidelines for meropenem using
broth macrodilution method. The MPC was determined using the agar plate
dilution method.
Result: The mean MPC of meropenem among meropenem sensitive group
was lower than meropenem resistant Acinetobacter baumannii group, P=0,124
([122,67 ± 104,02] vs [252,8 ± 189,7]). Mean MPC/MIC ratio of meropenem
among meropenem sensitive group was greater than meropenem resistant
Acinetobacter baumannii group, P=0,000 ([172,00 ± 173,34] vs [2,10 ± 0,91]).
MPC value of meropenem for Acinetobacter baumannii isolates from ICU
patients is 512 μg/mL because this value will cover all meropenem sensitive and
resistant Acinetobacter baumannii isolates.
Conclusion: There is no difference in MPC of meropenem between
sensitive and resistant Acinetobacter baumannii clinical isolates. The MPC/MIC
ratio of meropenem among meropenem sensitive group is greater than meropenem
resistant Acinetobacter baumannii group. The MPC value of meropenem for
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Acinetobacter baumannii isolates that should be given in ICU patients is 512
μg/mL.
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